Colorectal cancer (CRC) is the second leading cause of cancer associated deaths in developed countries. 22 Cancer progression and metastatic spread is reliant on new blood vasculature, or angiogenesis. Tumour-23 related angiogenesis is regulated by pro-and anti-angiogenic factors secreted from malignant tissue in a 24 stepwise process. Previously we structurally modified the small anti-angiogenic molecule quininib and 25 discovered a more potent anti-angiogenic compound 1, 4 dihydroxy quininib (Q8), an antagonist of 26 cysteinyl leukotriene receptor-1 with VEGF-independent bioactivity. Here, Q8, quininib (Q1) and five 27 structural analogues were assayed for anti-tumorigenic effects in pre-clinical cancer models. Q8 reduced 28 clone formation of the human colorectal cancer cell line HT29-Luc2. Gene silencing of CysLT1 in HT29-Luc2 29 cells significantly reduced expression of calpain-2. In human ex vivo colorectal cancer tumour explants, 30
Introduction 39
According to the American Cancer Society ~40% of patients with colorectal cancer (CRC) are diagnosed 40 with localised disease. As tumours depend on angiogenesis for growth and metastasis this biological 41 process is focal to anti-cancer drug development (1). The anti-VEGF biological bevacizumab was FDA 42 approved in 2004 for treatment of metastatic colorectal cancer (mCRC) in combination with Ironotecan, 43 5-fluorouracil and leucovorin (IFL) and in 2006 granted approval for second-line treatment of mCRC in 44 combination with 5-fluorouracil, leucovorin and oxaliplatin (FOLFOX) (2). However, bevacizumab only 45 extends life expectancy by approximately 4.7 months in 40% of patients and can cause gastrointestinal 46 perforation, hypertension and bleeding (3). The development of less toxic anti-angiogenic drugs with 47 improved efficacy is warranted. 48 49
Angiogenesis, a highly orchestrated process between endothelial cells and pericytes occurs pathologically 50 in response to hypoxia and inflammation in the tumour microenvironment. The progression and 51 metastatic spread of tumour cells is reliant on angiogenesis (4) and endothelial cells respond to factors 52 secreted from the malignant cells. Through the release of growth factors and direct contact with 53 endothelial cells, pericytes contribute to vessel maturation (6) while endothelial cells can regulate the 54 bidirectional movement of immune cells into and out of the blood. Inducers of angiogenesis include 55 vascular endothelial growth factors (VEGFs), angiopoietins (ANG's), transforming growth factors (TGFs), 56 platelet derived growth factors (PFGF), tumour necrosis factor-α (TNF-α), interleukins and fibroblast 57 growth factor (FGF) proteins. 58 TIE-1 and TIE-2 (also known as TEK) are receptor tyrosine kinases for the angiopoietin growth factor 59 ligands of which ANGPT1 and ANGPT2 are best characterized (5). TIE receptors are largely expressed in 60 the endothelium with expression also observed in a small subset of TIE-2 expressing 61 monocytes/macrophages (TEMs) (6). Recently, pericytes were reported to express TIE-2, albeit at a much 62 lower levels than endothelial cells (7) . In early tumour development, TIE-2 expressing TEMs are recruited 63
to solid tumours to facilitate their vascularization and growth (8). In pericytes, TIE-2 controls the 64 expression of Calpain1, a key regulator of cellular migration and invasion and important in tumour 65 neovascularisation (7) . The ANGPT-TIE pathway plays an important role in blood vessel development, 66 remodelling and stability influencing angiogenesis and metastasis (9). 67 68
Chronic inflammation is a predisposing factor for the development of many cancers, particularly for 69 colorectal cancers (10). Cysteinyl leukotrienes (CysLTs) LTC4, LTD4 and LTE4 are products of cell-membrane 70 bound arachidonic acid (AA) metabolism and can induce inflammation by activating the cysteinyl 71 leukotriene receptors CysLT1 and CysLT2 and the less functionally studied GPR99 (CyLT3) (14, 15) . Agonism 72 of CysLT1 by LTD4 can affect cell proliferation and cell cycle regulation (10, 11) . The connection between 73 angiogenesis and cysteinyl leukotriene signalling has been demonstrated using murine aortic ring models 74 (12) . Treatment of murine aortic explants with the CysLT1 antagonist Montelukast could block the growth 75 of vascular sprouts when cultured in 25% serum, however, antagonism of the CysLT2 using BAY-cyslt2 did 76 5 were identified in the kidneys (two animals at each dose) and in the heart (one animal at each dose) (data 159 not shown) ( Supp. Figure 1 C) . All tissue specimens in the 50 or 100 mg/kg Q8 group were histologically 160 within normal limits except for vascular calcification identified in the kidney of one animal and foci of non-161 specific, mild chronic lobular inflammation identified in the liver of one animal treated with 100 mg/kg Q8 162 (data not shown) (Supp. Figure 1 D) . All tissue specimens were histologically within normal limits in the 163 25 mg/kg Q8 group (Supp. Figure 1 E) . In summary, the MTD of Q1 was confirmed at 50 mg/kg and the 164 MTD of Q8 was determined at 50 mg/kg. There were no significant histological differences between 165 organs of the control group, Q8 (25, 50 and 100 mg/kg) and Q1 (50 and 100mg/kg) groups. 166 167 Q8 reduces tumour volume and bioluminescence in HT29-Luc2 xenografted mice 168
To determine if Q8 significantly reduces tumour growth in vivo, and to compare to quininib (Q1), CRC-169 specific murine xenograft models were created by subcutaneous injection of HT29-Luc2 cells using 170 immune-compromised mice (Balb/C nu/nu). Palpable tumours were evident and measurable with a digital 171 calipers 7 days post subcutaneous implantation of 2.5 x 10 6 HT29-Luc2 cells per mouse. 3 drug groups 172
(each with 6 animals) were treated by intraperitoneal injection every 3 days and included; 25 mg/kg Q1, 173 25 mg/kg Q8 or vehicle (10% DMSO). Treatment with 25 mg/kg Q1 significantly decreased tumour volume 174 (Figure 5 A) , as measured using callipers, compared to vehicle control (average final measurements: 175 633.59 mm 3 vs. 814.70 mm 3 , p<0.05). Treatment with 25 mg/kg Q8 also significantly reduced tumour 176 volume (Figure 5 A & C) compared to vehicle control (average final measurements: 553.31 mm 3 vs 814.70 177 mm 3 , p<0.001). On the final day of the study, the bioluminescent activity of tumours from all animals was 178 assessed following intraperitoneal luciferin injection. Bioluminescence of tumours was lowest in the Q8 179 group with Q8 bioluminescence being significantly lower compared to that of the control (average 180 bioluminescence 1.24 x 1010 photons/sec vs. 2.33 x1010 photons/sec, p<0.05) on day 41 (Figure 5 B & C) . 181 There was no statistically significant difference in bioluminescence between control and Q1 treatment 182 groups on day 41 of the study. There was no statistically significant difference in bioluminescence 183 between Q8 and Q1 treatment groups on day 41 of the study. The ex vivo tumours, livers and lungs of all 184 mice were imaged using the IVIS® spectrum to search for evidence of HT29-Luc2 cell metastasis but no 185 bioluminescence was observed in the lung or liver tissue taken from either control, Q1 or Q8 treated mice 186
indicating that the HT29-Luc2 cells of the primary subcutaneous tumour had not metastasized (Figure 5 187 D). In summary, Q8 significantly reduced tumour volume and tumour bioluminescence in HT29-Luc2 188
xenografted mice compared to vehicle control. 189 190
The effect of Q8 on the expression of angiogenic, apoptotic and proliferative markers in mouse 191 xenograft tumour tissue.
192
Immunohistochemical analysis of post-mortem xenograft samples revealed the level of proliferation 193 positivity, Ki-67, the apoptotic marker caspase 3 and TIE-2 were not significantly decreased in the 25 194 mg/kg Q8 treatment group compared to vehicle control (all p values > 0.05, Figure 6A -C). However, 195 following Q8 treatment, the levels of calpain were significantly decreased (Figure 6D , p<0.0001).
197
Discussion 198 Based on the robust anti-angiogenic activity of 1,4 dihydroxy quininib (Q8) (13) in comparison to the other 199 analogues tested, it was the analogue chosen to further test across different models. This study 200 7 vivo. The MTD of 1,4-dihydroxy quininib was determined at 50 mg/kg and repeated administration every 243 3-4 days over 3 weeks resulted in no significant histological changes. Notably at 25 mg/kg, 1,4-dihydroxy 244 quininib significantly reduced tumour volume and tumour bioluminescence compared to vehicle control. 245
Furthermore, 1,4-dihydroxy quininib reduced the expression of the pro-angiogenic factor calpain-2, 246
corroborating the earlier findings we detected in HT29-Luc2 cells. The reduction in calpain-2 expression 247 in xenograft tumours may serve as a novel outcome to complement existing anti-VEGF therapies for 248 colorectal cancer such as Bevacizumab. Calpains play a poignant role in tumour angiogenesis by regulating 249 the survival and migration of endothelial cells (20, 33) . Inhibition of calpains represents a novel anti-250 angiogenic strategy in cancer but such inhibition needs to be highly specific as m-calpain enables 251 endothelial cell migration but µ-calpain enables endothelial cell apoptosis and vascular regression (34).
252
VEGF stimulates endothelial cell migration by enhancing m-calpain (calpain-2) expression and activity 253 allowing tail retraction and this process can be reversed using calpastatin, an inhibitor of calpain-2 (19). 254
Although calpain-2 (m-calpain) orchestrates neovascularization, µ-calpain is responsible for cell apoptosis 255 and angiogenic regression (34), therefore, select and endothelial specific inhibition of m-calpain would be 256 of great importance in a cancer setting. Calpain-2 also plays a role in tumour and stromal cell invasion 257 during disassembly of focal adhesions at the rear of the tumour or stromal cell (35). While 258 immunohistochemical analysis of human colorectal adenocarcinomas have previously shown strong 259 expression levels of TIE-1 and TIE-2, which correlated with several clinicopathological factors (36) we 260 observed weak staining in our xenograft tissue and no change in expression following Q8 treatment in 261
vivo. This is in contrast to the changes we detect in human ex vivo explants treated with Q8. In the human 262 model the functional soluble TIE-2 was significantly reduced with Q8. The levels of secreted TIE-2 and the 263 level of total TIE-2 expression in tissue are measuring TIE-2 at different levels but the secreted TIE-2 is 264 suggested to be more functional. 265 266
Drug resistance remains a major problem with current therapies such as bevacizumab, sunitinib and 267 sorafenib, which target the VEGFR system, the chief regulator of angiogenesis. Numerous preclinical 268 studies of angiopoietin-TIE targeted treatment in oncology and ocular vascular diseases suggest 269 complementation with VEGF targeted therapy (6). Many studies aim to block the binding of 270 ANGPT1/ANGPT2 to TIE-2, thereby, inhibiting tumour growth. TIE-2 functionality and activation or indirect 271 inhibition of its expression is context-dependent. Inhibition of ANGPT2 and the subsequent activation of 272 TIE-2 by the ANG2 Binding TIE-2 Activating Antibody (ABTAA) improves vascular stabilization and drug 273 delivery in mouse models of orthotopic glioma, subcutaneous Lewis lung carcinoma and spontaneous 274 mammary cancer (37). TIE-2 expressing macrophages induce vessel destabilization, promote intravasation 275 of tumour cells in the primary tumour (6) and would consequently warrant a reduction in TIE-2 expression. 276
However, in pericytes, a pro-angiogenic effect was observed leading to enhanced tumour growth 277
following the deletion of TIE-2 (7). The importance of the ANGPT-TIE-2 signalling pathway which acts as a 278 link between angiogenesis and inflammation positions it as an excellent target to modify therapeutically. 279 280
In summary, 1,4-dihydroxy quininib may be an alternative therapeutic approach for patients who become 281 resistant to anti-VEGF drugs, possibly in combination with standard treatment for these patients. 282 283 8
Experimental Procedures 284 285
Cell culture 286 HT29-Luc2 Bioware® Ultra human colorectal cancer cells were purchased from (PerkinElmer/cat: 124353) 287
and were maintained at 37 °C / 5% CO2 in McCoy's 5A medium (Gibco) with L-glutamine (Gibco)  288 supplemented with 10% fetal bovine serum (FBS) (Gibco). 289 290
MTT assay 291 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) dye was used to determine the cytotoxic 292 effect of quininib and analogues on HT29-Luc2 cells. Cells were trypsinised using 2 ml TrypLE™ Express 293 (Gibco) and centrifuged at 1,200 rpm for 4 mins at RT. Cell pellets were re-suspended in full medium and 294 cells were counted and seeded into 96-well plates at a density of 10,000 cells/well. Cells were left to 295 adhere for 24 hours and serum starved for 24 hours. Medium was removed from HT29-Luc2 cells and 296 replaced with 10 μM drug solution, where 5-FU was used as a positive control and DMSO as a vehicle 297 control. HT29-Luc2 cells were incubated for 24, 48, 72 and 96 hours with drugs. Drug solution was 298 removed and wells were washed with PBS before adding 10 µl MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-299 diphenyltetrazolium bromide) dye to cells for 4 hours at 37 °C . 100 µl 100% DMSO was added to wells to 300 dissolve the formazan crystals which formed. The absorbance values were read at 570 nm using a 301
SpectraMax® M2 microplate reader. 302 303
Colony formation assay 304 HT29-Luc2 CRC cells were maintained in McCoy's 5A (Gibco) medium supplemented with 10% FBS (Gibco) 305 at 37 °C /5% CO2. Cells were washed in DPBS and trypsinised using 2 ml TrypLE™ Express (Gibco). Cells were 306 centrifuged following detachment at 1,200 rpm for 4 minutes. Cell pellets were re-suspended in full 307 medium and a cell count was performed using a haemocytometer. 1.5 x10 3 cells were seeded per well of 308 a 6-well plate and left to adhere for 24 hours. Cells were then treated with 10 μM or 20 μM of quininib 309 (Q1), Q8, Q18, Q22, P4 or P18 for 24, 48, 72 and 96 hours. The drugs were removed and cells were grown 310 in fresh media for 10 days in total, clones were then fixed using 4% paraformaldehyde and stained by 311 incubating with 0.5% crystal violet solution (Pro-Lab diagnostics PL7000) at RT for 2 hours. Clone counting 312
was performed using the ColCount™ system (Oxford Optronix). 313 314
CysLT1 expression 315 HT29-Luc2 cells were seeded at 250,000 cells per well of a 6-well plate and following adherence, cells 316
were serum starved for 24 hours. To assess CysLT1 expression, cytosolic and nuclear proteins were 317 extracted from cells. Cells were washed in ice-cold PBS and 200 µl Buffer A (10 mM HEPES pH 8, 1.5 mM 318
MgCl2, 10 mM KCl, 200 mM sucrose, 0.5 mM DTT, 0.25% IGEPAL (octylphenoxypolyethoxyethanol) and 1x 319 protease inhibitor) was added to each well and left for 5 minutes. Cells were scraped into an eppendorf 320
and were left to swell on ice for 15 minutes. 12.5 ul of 5% NP-40 (IGEPAL) (Sigma) was added to each 200 321 ul sample to give a final concentration of 0.3% NP-40) and samples were vortexed for 10 seconds each. 322
Cell lysates were centrifuged at 12,000 rpm for 2 minutes at 4 °C . Supernatant was removed from each 323 sample and stored at -20 °C as cytoplasmic fractions. The remaining pellet was washed in ice-cold PBS to 324 remove any remaining traces of cytoplasmic fraction and 50 ul of Buffer B (20 mM HEPES pH 8, 420 mM 325 NaCl, 0.2 mM EDTA, 1.5 mM MgCl2, 0.5 mM DTT, 25% glycerol and 1x protease inhibitor) was added to 326 the remaining pellet and the sample was sonicated for 5 seconds. Each sample was centrifuged at 327 14,000rpm for 10 min at 4 °C , and the supernatant was stored as nuclear fraction at -80 °C . Following 328 treatment of HMEC-1 cells with 10 µM Q1, Q8 or montelukast for 5 hours, total protein was extracted 329 from cells using ice-cold RIPA lysis buffer supplemented with sodium fluoride (Sigma), β-glycerol-330 phosphate (Sigma) protease inhibitor (Sigma) and phosphatase inhibitor (Sigma). Cells were washed with 331 ice-cold PBS and 100 µl ice-cold RIPA lysis buffer was added to each plate well. Cells were scraped into 332 eppendorfs and left at 4 °C on a roller for 30 minutes to completely lyse the cells. Samples were centrifuged 333 at 12,000 rpm for 15 minutes at 4 °C and supernatants were stored at -80 °C as whole cell lysates. Protein 334 concentrations were determined using the BCA protein assay kit (Fisher) & 100 mg/kg) intraperitoneally every 3 days for 28 days (if tolerated) to determine the maximum tolerated 368 dose (MTD). Each treatment group consisted of 3 mice (n=3). Any score of 4 from multiple observations 369 or a score of 3 from a single observation resulted in immediate euthanasia of the mouse by CO2 370 asphyxiation. As the 100 mg/kg dose was deemed toxic, the animals of concern were subsequently 371 euthanized 3 days after the initial 100 mg/kg Q1 dose and 4 days after the initial 100 mg/kg Q8 dose 372 according to ethical guidelines. All animals were euthanized at the end of the study and necropsy was 373 performed. The following organs were removed from each mouse and stored in 10% neutral buffered 374 formalin (Sigma): brain, heart, lungs, kidneys, liver, small intestine and large intestine. Organs were 375 processed using a Tissue-Tek ® Tissue Processor and paraffin embedded. Tissue sections were cut, 376 deparaffinized and stained with hematoxylin and eosin. Tissue sections were analysed for gross 377 morphological abnormalities by our collaborating pathologist (RD). 378 379
Q8 tumour xenograft study 380
To determine if Q8 has enhanced effects on reduction of tumour growth compared to Q1, (previously 381
shown to reduce tumour growth in mice), both drugs were tested on tumour growth by creating an 382 optimized CRC-specific murine xenograft model by subcutaneous injection of 2,500,000 HT29-Luc2 cells 383
in immunocompromised mice (Balb/C nu/nu). HT29-Luc2 cells were grown to 80% confluence, were 384 recorded at passage 11 (p11) before use in the in vivo Q8 study and were kept on ice before subcutaneous 385
injections. The Q8 study consisted of 6 mice per treatment group (n=6). Q8 was administered to mice by 386 intraperitoneal injection every three days. Palpable tumours were evident and measurable with digital 387 calipers (Scienceware ® Digi-Max ™ slide caliper/cat: Z503576) 7 days post subcutaneous implantation of 388 the HT29-Luc2 cells. When palpable tumours measured ≥100 mm 3 , mice were injected with drugs 389
intraperitoneally using a 26-gauge needle (26G) every three days for ~5 weeks. A tumour volume sheet 390 was used to record tumour measurements every second day. Tumour volumes were calculated as per the 391 following formula:
(
. The appearance, weight, 392 behaviour, respiration and level of tumour induced skin lesions of all mice were recorded every three days 393 using the welfare score sheet (supplementary data). In keeping with ethical obligations outlined in AREC-394 P-11-42, if a tumour became necrotic, grew beyond 15 mm in diameter or became ulcerated, the animal 395 was euthanized via CO2 asphyxiation. On day 41 of the study, one mouse receiving 10% DMSO was 396 euthanized due to grade 2 wet ulceration of the subcutaneous tumour. Prior to euthanasia of this control 397 mouse, all animals in the study were intraperitoneally injected with 150 mg/kg (150 μl) of D-Luciferin (15 398 mg/ml) (Perkin-Elmer) 10 minutes before being imaged using the IVIS ® Spectrum in vivo imaging system 399 (Perkin-Elmer) to compare the bioluminescence of tumours between treatment groups. Following 400 imaging, all animals were euthanized by CO2 asphyxiation and tumours were harvested by excision 401 dissection and stored in 10% formalin or snapped frozen in liquid nitrogen for downstream histological 402 analysis or protein extraction. To determine if metastases from subcutaneous tumours in mice had 403 occurred, the liver and lungs were from removed from each animal of the Q8 tumour xenograft study 404 immediately following euthanasia. This was done by making an incision through the peritoneum to expose 405 the abdomen using a scissors. The liver and lung were gently cut out of the abdomen using a forceps and 406 scissors. The organs were bathed in a 15 mg/ml solution of D-Luciferin and placed in a transparent petri-407 11 dish. The organs were placed beside the corresponding excised xenografted tumour tissue and imaged 408 using the IVIS ® Spectrum in vivo imaging system. 409 410
Immunohistochemistry 411 Xenograft slide sections were deparaffinized and rehydrated and tissue antigens unmasked using 1X 412
Trilogy (Cell Marque) for 10 minutes in a pressure cooker. Sections were placed in fresh Trilogy solution 413
for 5 minutes and in distilled water for a further 5 minutes. Slides were then placed in a 3% hydrogen 414 peroxide solution (Sigma) for 30 minutes to quench endogenous peroxide activity. Slides were washed for 415 5 minutes in PBS three times and blocked to prevent non-specific antibody binding using goat serum (for 416 rabbit antibodies) and horse serum (for mouse antibodies) (Vector Vectastain ABC mouse kit Vector 417
Vectastain ABC rabbit kit). Primary antibodies were incubated with slide sections for 1 hour at RT at the 418 following concentrations; Calpain-2 (Aviva Systems Biology) 10 µg/µl; Cleaved caspase 3 (Cell Signaling 419 1:50); Ki-67 (Dako 1:75); TIE-2 (Abcam, 1:100). Slides were washed for 5 minutes in PBS three times and 420 incubated with biotinylated anti-rabbit or anti-mouse secondary antibodies (Vector Vectastain ABC kits) 421
for 30 minutes at RT. Slides were washed for 5 minutes in PBS three times and incubated with ABC reagent 422 for 30 minutes before staining with DAB (3, 3'-Diaminobenzidine tetrahydrochloride) (Sigma) and 423 counterstaining nuclei with haematoxylin (Sigma). Slide sections were gradually dehydrated by incubating 424 in 50%, 75%, 96% and 100% ethanol solutions, each for 3 minutes and cleared in Xylene (Sigma) overnight. 425
Tissue sections were manually mounted with coverslips using DPX mounting medium (Sigma) and slides 426
were left to dry overnight at RT. Slide sections were imaged at 20X magnification using a Nikon Eclipse 427 E200 with OptixCam Summit series camera and OCView 7 software. The intensity of staining was graded 428 semi-quantitatively in a blinded fashion by two observers (CB & AB) as negative "0", weak "1", moderate 429 "2" or strong "3" and the positivity of staining was documented as 0% (no cells stained), 10% (some cells 430 are stained but not 1/4 of cells stained), 25% (1/4 of cells stained), 50% (1/2 of cells stained), 75% (3/4 of 431 cells stained), 90% (greater than 3/4 of cells stained but not all cells stained) or 100% (all cells stained). 432
Immuno-histochemical staining for Ki-67 was performed in Beaumont hospital whereby deparaffinization, 433
antigen retrieval and IHC staining for Ki-67 was performed on an automated platform (Bond™ III system -434
Leica MicroSystems™, Newcastle, U.K.). Slides stained with Ki-67 were scored for positivity only. bicine and 150mM sodium chloride (pH 7.6)) supplemented with 10 μl/ml protease inhibitor (Roche) and 464
the BCA (Fisher) assay kit was used to quantify total protein extracted from explant tissue in μg/ml as per 465 the manufactures instructions. 20 µg protein was analysed per sample using the calpain-2 ELISA according 466
to the manufacturer's instructions. Total protein was extracted from each piece of tumour explant tissue 467 using ice-cold T-PER lysis reagent (Fisher) (proprietary detergent with 25 mM bicine and 150 mM sodium 468 chloride (pH 7.6)) supplemented with 10 μl/ml protease inhibitor (Roche) to normalise angiogenic factor 469 secretion from the ELISA to the amount of protein in each piece of tumour. Each piece of tissue was placed 470
in a tube with 300 μl ice cold T-PER reagent and a 3 mm stainless steel bead (Qiagen). The tubes were 471 placed in a TissueLyser II (Qiagen) for 2.5 minutes to completely homogenise the tissue, the lysate was 472 centrifuged at 13,000 rpm at 4 °C for 5 minutes and the supernatant was used immediately or stored at -473 80 °C . The BCA (Fisher) assay kit was used to quantify total protein extracted from explant tissue in μg/ml 474 as per the manufacturer's instructions. 475 476
Statistical Analysis 477
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